Celgene_rrDLBCL_Manuscript_Supplementary_Tables_8.5.21_R3-2.xlsx (125.09 kB)
Download file

Supplementary Tables: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.xlsx

Download (125.09 kB)
dataset
posted on 20.08.2021, 12:32 by Saaya Tsutsué, Shinichi Makita, Jingbo Yi, Bruce Crawford

Supplementary Table 1. Exchange rate and inflation rate conversion table.

Supplementary Table 2. Additional baseline and treatment characteristics

Supplementary Table 3. Distribution of patients by age group in each index regimen

Supplementary Table 4. Median index dosage for each regimen

Supplementary Table 5. Healthcare resource utilization during the follow-up period, by line of therapy and by index regimen.

Supplementary Table 6. Age at SCT by age groups and line of therapy

Supplementary Table 7. Adjusted direct nominal medical costs during the follow-up period, by line of therapy and by index regimen.

Supplementary Table 8. Additional HCRU results for COVID-19 analysis.

Funding

Celgene KK

Brystol Myers Squibb Company

History